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ABSTRACT  
 
Ischemic heart disease including myocardial infarction is developing on the basis of 
several risk-factors and co-morbidities such as obesity, diabetes, hypertension, and 
hypercholesterolemia. Ischemic heart disease is the leading cause of mortality 
worldwide, therefore, identification of drug targets for cardioprotection is of great 
clinical importance. Ischemic preconditioning, postconditioning, and remote 
conditioning trigger endogenous cardioprotective mechanisms that render the heart 
more resistant to lethal ischemic-reperfusion injury. However, major cardiovascular 
co-morbidities such as hyperlipidemia, diabetes, and their co-medications interfere 
with these cardioprotective mechanisms thereby limiting the efficacy of 
cardioprotective ischemic conditioning maneuvers. Ischemia reperfusion injury and 
cardioprotection by conditioning have been shown to affect global myocardial gene 
expression profile at the transcript level. Further understanding and the 
comprehensive analysis of the cardioprotective gene expression fingerprint in 
normal, protected, and in comorbid conditions may lead to identification of novel 
molecular targets for cardioprotection.  
 
 
KEY WORDS: mRNA, miRNA, microarray, microRNA, preconditioning, proteomics, 
postconditioning, risk factors, sequencing, system biology, transcriptomics 
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I/R – ischemia/reperfusion 
MAPKAP kinase - mitogen-activated protein kinase-activated protein kinase 
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1. Ischemic conditioning of the heart  
 
Ischemic conditioning leads to remarkable cardioprotection against I/R injury (see for 
extensive reviews:(1, 2). Ischemic conditioning has 3 major forms, preconditioning, 
postconditioning, and remote conditioning. In ischemic preconditioning, brief 
episodes of ischemia/reperfusion are applied before a prolonged ischemic event that 
would otherwise lead to significant irreversible tissue injury. Ischemic preconditioning 
is the most effective cardioprotective mechanism that evokes cardioprotection (3) 
immediately after the triggering ischemic cycles and in a delayed manner (appearing 
12-24 hours after the triggering ischemic cycles and lasting for approx. 72 hours) the 
latter termed as the second window of protection (4). In ischemic postconditioning, 
very brief episodes of ischemia/reperfusion are applied right after the prolonged 
ischemic event. In remote ischemic conditioning, brief cycles of non-lethal 
ischemia/reperfusion are applied to an extracardiac organ before, during, or after the 
prolonged ischemic event. The cardioprotective effectiveness of pre-, post-, and 
remote conditioning has been well established in preclinical models as well as in 
clinical studies (see for reviews:(2, 5, 6), however, its effectiveness is limited by the 
presence of several risk factors, comorbidities, and co-medications (see for 
extensive reviews:(1, 7, 8). Moreover, in spite of 3 decades of intense research on 
the cellular mechanism of conditioning, it is still not completely understood. 
Therefore, no drug targets could be identified so far that led to the development of a 
cardioprotective drug until market launching. This fact urges to find novel 
approaches to increase the translational value of preclinical studies (see for review 
(9)) and to find valid drug targets and novel therapeutic approaches for 
cardioprotection (see for review: (1, 10) and Table 1).  
 
In this review, we describe how assessment of changes in cardiac gene expression 
profile triggered by conditioning may facilitate the development of cardioprotective 
drugs that mimic the remarkable cardioprotection achieved by ischemic conditioning 
maneuvers. 
 
2. Gene expression of the heart in cardioprotection by ischemic 
conditioning 
There is a continuously increasing interest in ischemic conditioning of the heart 
as shown by the increasing number of papers in PubMed. Although there are a total 
of more than ten thousand of papers in the literature on cardioprotection by ischemic 
conditioning, less than 1% of these studies looked at global gene expression profile 
of the heart in response to ischemic conditioning. These studies have shown that 
preconditioning and postconditioning significantly affect the gene expression profile 
of the ischemic heart at the transcript level. The first studies in the literature showing 
that ischemic early and late preconditioning affects the gene expression profile of the 
heart using 1, 2 or 3 cycles of 5 min ischemia/5 min perfusion in rabbits or in isolated 
rat hearts, respectively, are more than 10 years old (11-13). In rabbit hearts, 35 
genes with significantly altered expression patterns in response to preconditioning 
were discovered including upregulated MAPKAP kinase 3 and cathepsin G genes in 
the preconditioned region, and GTP exchange factor, Na+/K+-ATPase, Zn finger 
protein 35, cytochrome c oxidase, mitogen-responsive phosphoprotein, and Ran-
binding protein in the non-ischemic region (14). In rat hearts, oligoadenylate 
synthase, chaperonin subunit epsilon, a cGMP phosphodiesterase (PDE9A1), a 
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secretory carrier membrane protein, an amino acid transporter, and protease 28 
subunit genes were changed in response to preconditioning (12).  
 
These early studies have been confirmed by several papers showing that both 
ischemic preconditioning and postconditioning trigger a cardioprotective gene 
expression profile of the heart at the transcript level (15-17). In line with these 
findings, changes in the expression of the post transcriptional regulators of gene 
expression, i.e. microRNAs have been recently shown by preconditioning and 
postconditioning in rat hearts (18). Whether remote ischemic conditioning may also 
affect global gene expression profile of the heart has not been specifically studied so 
far, although the early study of Simkhovich et al. (11) showing that the gene 
expression profile of the non-ischemic remote area was changed suggests that 
remote conditioning also leads to a cardioprotective genomic program. Accordingly, 
one paper has reported cardiac gene expression profile alterations following remote 
ischemic preconditioning; e.g. up-regulation of genes involved in oxidative stress 
(e.g. peroxiredoxin 4, platelet-derived growth factor receptor) 15 min or 24 hours 
after 6 cycles of 4-min femoral artery occlusion/reperfusion in mice (19). In line with 
this assumption, extracellular vesicles, potential carriers of microRNAs, have been 
shown to mediate the cardioprotective effect of remote ischemic preconditioning (3 × 
5-5 min) in rats (20).  
Identification of global gene expression profile of the heart in response to 
ischemic conditioning may help to identify key cellular pathways of 
ischemia/reperfusion injury and cardioprotection by ischemic conditioning. The 
transcription factor ZAC1 gene has been identified as potential target for gene 
silencing as this gene was significantly down-regulated by preconditioning and 
postconditioning (21). Similarly, by a systematic comparison method looking at the 
direction of microRNA expression changes after ischemia/reperfusion injury with or 
without preceding preconditioning or subsequent postconditioning, respectively, 
potential cardioprotective microRNA targets have been identified and termed 
“protectomiRs”, e.g. mimics of microRNA-139-5p, -125b*, let-7b, and antagomiR of 
microRNA-487b in rat hearts (18). These preclinical results show that by assessing 
the cardioprotective gene expression profile of the heart subjected to 
ischemia/reperfusion with or without cardioprotection elicited by ischemic 
conditioning, novel targets for cardioprotection can be identified. However, no data 
on the cardioprotective gene expression fingerprints in the human heart are available 
so far. 
 
3. Influence of co-morbidities on cardiac gene expression pattern  
The mechanism by which the remarkable cardioprotective effect of ischemic 
conditioning is attenuated or abolished in the presence of major risk factors, 
comorbidities, and their routine drug treatments is not exactly known (see for 
extensive reviews: (1, 7, 8). Therefore, for successful cardioprotective target 
identification and validation, it is of great importance to assess the effect of 
comorbidities and co-medications (see for review: (1)). Accentuated myocardial 
oxidative stress has been reported in the presence of major comorbidities. 
Therefore, it is plausible to speculate that redox signaling-dependent global gene 
expression changes contribute to the pathological phenotypes. The redox-sensitive 
modulation of gene expression may occur both by direct oxidative/nitrative 
modification of the transcription factor itself or by posttranslational modifications (i.e, 
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mainly phosphorylation/dephosphorylation) due to alterations in redox-regulated 
intracellular signaling cascades (e.g. p38 MAPK) (22).In this chapter we will review 
how major comorbidities may affect cardiac gene expression profile. 
 
3.1  Hyperlipidemia, obesity and statins 
Hyperlipidemia and obesity are amongst the most important risk factors for 
cardiovascular diseases due to their steeply increasing prevalence worldwide. To 
better characterize the effect of these pathologies on the heart, and to uncover novel 
therapeutic targets several research groups have performed systematic analyses of 
cardiac gene expression in various disease models. 
A few publications aimed to decipher how the composition of consumed excess fat 
influences gene expression in the heart. Lockridge and colleagues hypothesized that 
exposure to various fatty acids alone have differential effect on the gene expression 
pattern of isolated cardiomyocytes. They compared effects of fatty acids considered 
cardioprotective and cardiotoxic by cDNA microarrays and revealed that 24 h 
treatment of saturated fatty acids tended to induce endoplasmic reticulum- and 
oxidative stress markers (e.g. activating transcription factor 3 or growth arrest and 
DNA-damage-inducible protein α) more than a treatment with unsaturated fatty acids 
(23). The acute effects of unsaturated FAs on gene expression in the heart were 
studied in-vivo as well. Mice were fed with triglycerides comprising specific FAs, and 
6 h later mRNA expression profiles of the hearts were determined. Similarly to the 
experiment on isolated cells, a differential modulation of gene expression was 
shown, where linolenic acid (C18:3) modulated the expression of most genes, the 
majority of which was related to the PPARα signaling pathway (e.g. heme oxygenase 
1 or angiopoietin-like 4 protein) (24). These studies clearly demonstrate that even a 
short term overload of dietary fats might modulate cardiac gene expression, and that 
these effects are specific to fatty acid moieties and most likely not a direct 
consequence of the cellular energy imbalance. 
Long term effects of hyperlipidemia and obesity on cardiac gene expression has 
been studied in several papers. In an early study, Puskas et al reported that in the 
hearts of rats on cholesterol-enriched chow for two months expression of numerous 
genes were modulated, including members of energy metabolism (e.g. NADH-
ubiquinone oxidoreductase), heat shock proteins (heat shock protein 86), ion 
channels (sodium/potassium ATPase), and structural proteins (procollagen, type III, 
α1) (25). Later, Sarkozy et al described differences in gene expression between 
Zucker diabetic fatty and control lean rats including several metabolic enzymes (e.g. 
argininosuccinate synthetase), stress response proteins (e.g. heat shock protein 70, 
1A) and ion channels (e.g. sodium/potassium ATPase β4 polypeptide) (26). Several 
of these genes we have not been implicated in cardiovascular diseases before. 
Tissue specific gene expression changes were also compared in obese animals (27). 
In high-fat chow fed mice expression of several hundred genes is altered, although 
only a fraction of them is common between tissues. In the heart most robust changes 
were detected in members of lipid metabolism (e.g. major urinary proteins 2, 3 and 
5), but in contrast, in the adipose tissue expression of several genes of the immune 
system were altered (e.g. CD84 antigen). In addition, a profound modulation of 
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PPAR signaling in most tissues is shown in this publication, similarly to others, e.g. 
(24).  
Large animal models are rarely used for cardiac transcriptomics studies. Rouet and 
colleagues investigated dogs after 9 weeks of high fat diet that lead to an 
approximately 25% weigh gain and arterial hypertension. This treatment resulted in a 
profound alteration of atrial and ventricular gene expression (28). They identified 
several metabolic enzymes (e.g. cytochrome C oxidase), ion channels (e.g. 
sodium/potassium ATPase), genes involved in protein synthesis and remodeling 
(e.g. matrix metalloprotease 9, or nuclear factor erythroid 2–related factor 2). 
Interestingly, most gene expression changes have been detected in the atria and not 
the left ventricle. For example, they assessed a decrease in phospholamban and 
sarco-endoplasmic reticulum Ca2+-ATPase-2 (SERCA-2) mRNA level only in the 
atria. In a following study, they studied temporal changes in gene expression as well. 
Dogs were fed with high-fat chow for 9-24 weeks and left ventricular mRNA levels 
were assessed by microarrays (29). In these experiments they identified a time-
dependent decrease in the ventricular expression of phospholamban and SERCA-2. 
At 24 weeks they also found a decrease in myostatin expression, and an up-
regulation in the expression of several genes related to the TGF-β pathway, which 
are also implicated in obesity-related cardiac pathologies, such as hypertrophy and 
excessive fibrosis. 
The effect of human obesity or hyperlipidemia on cardiac gene expression patterns 
is not well studied. Philip-Couderc et al investigated mRNA transcript levels from 
right atrial appendages of obese and lean patients. They reported that obesity 
modulates the expression of almost 400 genes in the heart, and showed that the 
most affected signaling pathway was the down-regulated Wnt system, which is 
involved in cardiac hypertrophy (30). Although this report shows that the gene 
expression pattern of the human atrium is severely altered in obesity, so far data is 
unavailable from ventricular samples. Given that the overlap in reported gene 
expression changes between species and models seem to be low, studies on 
obesity- and hyperlipidemia-modulated gene expression is still warranted. 
During the last decade an increasing number of researchers directed their focus on 
the systematic analysis of miRNAs in the cardiovascular system. We recently 
reported that expression of several miRNAs is altered in the ventricles of rats fed a 
cholesterol-enriched chow (31). One of the most robust down-regulation was found 
in miR-25, which might be responsible for the increased oxidative- and nitrosative 
stress observed in this model, since one of the putative targets of miR-25 is NOX4, a 
major source of reactive oxygen species. The role of miRNAs in hyperlipidemia- and 
obesity-induced changes in gene expression was also studied in the liver of mice on 
high-fat diet (32). They found that hepatic expression of miR-27b is elevated in 
obese animals. The study concluded that miR-27b is a key regulator of hepatic lipid 
metabolism since the expression of its several target genes were also altered in 
hyperlipidemia. One might suggest that cardiac lipid metabolism can also be 
influenced by miRNAs through the circulation. Indeed, it has been reported that the 
overexpression of miR-27b leads to cardiac dysfunction and hypertrophy in mice 
(33), however, elsewhere it was identified as an anti-hypertrophic miRNA (34). As in 
case of mRNA transcriptomics studies, data on cardiac expression of miRNAs in 
hyperlipidemic or obese humans is missing. 
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Statins, as inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A reductase, are 
potent cholesterol-lowering drugs that are widely used in clinical practice for the 
primary and secondary prevention of coronary heart disease. Statins can exert 
pleiotropic effects aside from lowering cholesterol and blood pressure through 
several different pathways including the induction of endothelial nitric-oxide synthase 
expression, anti-inflammatory actions, and antioxidant activity (35). We have 
previously shown in isolated rat hearts that lovastatin interferes with ischemic pre- 
and postconditioning (36). However, only a handful of preclinical studies investigated 
the effects of statin treatment on cardiac gene expression pattern. In a comparative 
study different types of statins such as atorva-, prava-, pitava-, and rosuvastatin, 
were administered orally to normal C57Bl/6 mice for 4 weeks (37). The authors 
found altogether 49 genes to be up- or down-regulated by statin treatments in a 
drug-specific manner, from which tissue inhibitor of metalloproteinases-3 showed the 
most robust increase in response to atorvastatin treatment. Others reported on 
cardiac expression changes of 93 genes after 4-week atorvastatin (15 mg/kg/day) 
treatment in normal Wistar Kyoto rats, whilst cardiac mRNA level of 60 genes has 
been altered by the same treatment in stroke prone spontaneously hypertensive rats 
(38). The altered genes included genes involved in general metabolic pathways 
(glucose, fatty acid, and cholesterol biosynthesis, etc.), cell division, signaling, 
motility, cell/organism defense, regulation of protein expression, oxidative stress, and 
inflammatory processes. Despite the abundancy of clinical studies investigating the 
effects of statins, comprehensive studies on the effect of statins on cardiac gene 
expression profiles in the healthy and ischemic human myocardium are still missing. 
 
3.2 Diabetes 
Diabetes-related metabolic and molecular alterations ultimately lead to complex and 
serious cardiovascular complications, involving accelerated progression of 
atherosclerosis and deterioration of cardiac function (39). Diabetic myocardial 
dysfunction and diabetic cardiomyopathy is the factor that is responsible for higher 
cardiac morbidity and mortality in diabetics (40). It is well established now that 
multiple factors contribute and promote to the development and evolution of diabetic 
cardiomyopathy (these include hyperglycemia and subsequent insulin resistance, 
increased fatty acid metabolism, microcirculatory changes, sympathetic dysfunction, 
myocardial inflammation, oxidative/nitrative stress, remodeling and fibrosis), however 
the exact molecular events that initiate and fuel these pivotal pathological 
mechanisms are not entirely clear (41). To understand the underlying biological 
processes and identify new molecular targets, detailed characterization of gene 
expression in these hearts with systems biological tools is of high importance. 
Investigations in pre-diabetic models are clinically essential, due to the enormously 
increasing incidence and overlapping prevalence of metabolic syndrome and pre-
diabetes (42). There is also evidence for the deterioration of myocardial function in 
models of pre-diabetes (43-45), in line with these, recently we have reported marked 
global gene expression alterations in the heart Zucker diabetic fatty rats (26), a 
model that is characterized by main features of pre-diabetes and metabolic 
syndrome (obesity, hyperglycemia, hyperinsulinemia, and hypercholesterolemia). 
Among the 14921 transcript assessed, 10244 showed detectable expression in the 
heart. Altogether 85 transcripts showed significant alterations (up- or down-
regulation), when compared to the lean control rats. The detailed analysis (involving 
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functional clusterization and gene ontology analysis) showed alterations in 
transcripts of lipid metabolism (e.g. 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 2; argininosuccinate synthetase; 2-amino-3-ketobutyrate-coenzyme A 
ligase), extra- and intracellular structural proteins (e.g. myosin IXA; aggrecan1), 
signal transduction (e.g. activating transcription factor 3; phospholipase A2) stress 
response (e.g. heat shock 70kD protein 1A; heat shock protein 60; glutathione S-
transferase Yc2 subunit), ion channels and receptors (e.g. ATPase, Na+/K+ 
transporting, beta 4 polypeptide; ATPase, H+/K+ transporting, non-gastric, alpha 
polypeptide). These profound modifications in the cardiac transcriptome might be 
involved in the development of cardiac pathological abnormalities induced by pre-
diabetes and metabolic syndrome.  
Similar comprehensive studies were carried out in recent years in different models of 
overt diabetes, either using genetic models of the disease (Goto-Kakizaki diabetic 
rats, Otsuka Long-Evans Tokushima fatty rats) or the streptozotocin-induced type I. 
diabetes model. Karakikes et al. revealed significant divergence in myocardial gene 
expression profile in the hearts of the diabetic Otsuka Long-Evans Tokushima fatty 
rats when compared to the non-diabetic controls (46). Out of the 20500 transcripts 
surveyed, 838 showed divergent expression (272 up-regulations and 566 down-
regulations). They subsequent functional analysis indicate that diabetic 
cardiomyopathy in this type 2 diabetes model associated with changes in transcripts 
involved in immunity, development, intracellular signaling, cell proliferation and 
transcription regulation.  
 
There is also evidence for the profound effect of diabetes on deteriorated post-
infarction remodeling. The adverse remodeling process in diabetes is in association 
with profound myocardial gene expression alterations. The study by Song et al. 
suggest that in type 1 diabetic rats transcriptomic changes are responsible for 
altered myocardial metabolic substrate utilization (affected fatty acid metabolism, 
carboxylic acid synthesis, steroid metabolisms), that may account for the 
exaggerated progression of post-infarction remodeling processes (47).  
 
Gestational diabetes is a specific diabetic condition, affecting both the health of the-
mother and the baby. Although, there is a three- to four fold increase in the incidence 
of congenital heart defects caused by maternal diabetes (48), the exact molecular 
mechanisms that contribute to the teratogenic effects of the diabetic milieu are not 
known. A recent study investigated gene expression profiles of developing hearts of 
embryos, aiming to shed light on the mechanisms of cardiac malformation 
development (49). The study revealed several differentially expressed genes in 
healthy and diabetic embryonic hearts. Based on the functional categorization of the 
altered transcripts it is hypothesized that genes involved in lipid metabolism, cell 
cycle and transcription regulation have important role in cardiac embryopathy.  
Although, transcriptomic tools have revealed several important gene expression 
alterations in the heart in diabetic conditions, several limitations have to be noted. In 
the last years it became evident that the fate of the mRNA is determined by presence 
of other regulatory non-coding RNA species (e.g. microRNAs). In addition the 
importance and extent of alternative splicing events in cardiac pathologies are now 
recognized (50) that are impossible to assess with conventional microarray-based 
tools. In line with these, reactivation of the fetal splicing gene program has been 
described by Verma et al. (51). RNA sequencing and subsequent bioinformatics 
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identification of splicing events revealed that several important transcripts implicated 
in diabetes (e.g. VEGF, Mef2a) undergo alternative splicing. In addition there is a 
significant similarity of splicing pattern in the diabetic and developing embryonic 
heart, indicating the reprogramming of fetal gene expression events. 
Recent studies also indicate the importance of microRNAs in the development of 
diabetic myocardial pathologies. The concordant studies of the Hu lab indicate 
striking alterations in microRNA expression profile in the heart of streptozotocin 
treated rats, implicating alterations in whole gene networks (52, 53). They identified 
19 microRNAs that were dysregulated in diabetic hearts (up-regulation of miR-195, 
miR-199a-3p, miR-142-3p, miR-24, miR-21, miR-208a, miR-221, miR-499-3p, miR-
700, and miR-705 and down-regulation of miR-1, miR-143, miR-29, miR-20a, miR-
220b, and miR-373). Based on bioinformatic target prediction and partial 
experimental validation, it seems that the affected microRNAs have a significant 
fingerprint on myocardial transcriptomic profile (affected genes involve hypertrophy- 
and fibrosis-related targets). 
In addition, accumulating evidence prove now the applicability of microRNAs as 
diagnostic biomarkers. In a landmark study Zampetaki et al. determined plasma 
microRNA expression profiles in diabetic patients (54), revealing 5 candidate 
microRNAs (miR-15a, miR-29b, miR-126, miR-223, and miR-28-3p) to be used as 
diagnostic indicators and predictors of later onset diabetes. 
The prevalence of diabetic neuropathy is greater than 50% in patients with long-
standing diabetes (55). Although, several papers have been published investigating 
the gene expression changes in different neural structures during the development of 
diabetic neuropathy, it is not clear if diabetes affects cardiac gene expression due to 
sensory and/or motor neuropathy. Capsaicin, an essential compound of hot pepper, 
is used as topical treatment to alleviate severe pain in patients with diabetic 
neuropathy (56). Capsaicin is a highly selective sensory neurotoxin that leads to a 
selective functional blockade of a primary sensory neurons (57), (58). We have 
previously shown that capsaicin-sensitive sensory nerves play an important role in 
preconditioning in rat hearts (59). Furthermore, we demonstrated that capsaicin-
sensitive nerves are involved in the regulation cardiac NO-cGMP signaling (60), 
which is known to be one of the major regulatory pathways for ischemic conditioning. 
Moreover, we have also shown that selective chemodenervation of capsaicin-
sensitive sensory nerves in male Wistar rats in vivo, beyond cardiac diastolic 
dysfunction, induced changes in myocardial gene expression (61). In this study, 
among the 6400 rat genes examined by DNA microarray and/or by QRT-PCR, 47 
genes exhibited significant up-regulation and 36 were down-regulated. The up-
regulated genes affect neural functions (e.g. vanilloid receptor 1; GABA receptor rho-
3 subunit), signal transduction (including NO signaling), cell adhesion (integrin α v 
subunit), gene regulation (histone deacetylase 2), and metabolic pathways 
particularly the lipid (apolipoprotein B, farnesyl transferase) metabolism. Among the 
repressed genes we have also found genes of metabolic pathways (e.g. aldehyde 
dehydrogenase), cell cycle regulators (cyclin-dependent kinase 4), matrix 
metalloproteinase 13, and interleukin 7. 
 
4. Conclusions and perspectives 
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By assessing global cardiac gene expression profile of the ischemic heart with or 
without cardioprotection by ischemic conditioning, one may explore the 
cardioprotective gene expression fingerprint and identify novel drug targets for 
cardioprotection (Table 1.). However, for identification of valid drug targets, the effect 
of risk factors, comorbidities, and co-medications of ischemic heart disease should 
be taken into account. There is also an unmet need for studies that utilize an 
integrated “omics” approach (mRNA and non-coding RNA transcriptomics followed 
by proteomic analysis) with subsequent robust bioinformatics (e.g. network analysis) 
to identify key regulatory networks and signaling hubs in response to 
cardioprotection (Figure 1. (62, 63)). So far very few studies looked at changes in the 
gene expression profile of the ischemic heart in response to cardioprotection and its 
confounding factors. However, such studies would be necessary to identify key 
pathways of cardioprotection that are still active in the presence of major 
cardiovascular comorbidities and their routine medications.  
 
Acknowledgements  
This work was supported by the following grants: Hungarian Scientific Research 
Fund and the Austrian Science Fund (OTKA ANN 107803). ZG and PB hold „János 
Bolyai Fellowship” from the Hungarian Academy of Sciences. ZVV was supported by 
the National Program of Excellence (TAMOP 4.2.4.A/1-11-1-2012-0001and by the 
Scientific Merit Award of the Semmelweis University. PF is a Szentágothai Fellow of 
the National Program of Excellence (TAMOP 4.2.4.A/2-11-1-2012-0001). 
  
12 
 
Table 1. Examples for potential targets revealed by functional genomics 
approaches 
   Target   Role   Reference 
Ischemic conditioning 
   MAPKAP kinase 3   signaling  (11) 
cathepsin G   protease  (11) 
   PDE9A1   phosphodiesterase  (12) 
   peroxredoxin 4  antioxidant defence (18) 
PDGFR   signaling  (18) 
   ZAC1    transcription factor (20) 
   microRNA-139-5p  unknown  (17) 
microRNA-125b*  unknown  (17) 
let-7b    unknown  (17) 
microRNA-487b  unknown  (17) 
Hyperlipidemia and obesity 
   ATF3    transcription factor (22) 
   NADH-ubiquinone   energy metabolism (24) 
oxidoreductase 
   Hsp86    stress response (24) 
   procollagen   structural proteins (24) 
   argininosuccinate   Arg metabolism (25) 
synthetase 
Hsp70    stress response (25) 
   cytochrome C oxidase energy metabolism (27) 
   MMP-9   remodeling  (27) 
   microRNA-25  oxidative stress (30) 
   microRNA-27b  hypertrophy  (31-33) 
Diabetes 
   vanilloid receptor 1  signaling  (60) 
   histone deacetylase 2 gene regulation (60) 
13 
 
   apolipoprotein B  lipid metabolism (60) 
   MMP-13   remodeling  (60) 
microRNA-208a  hypertrophy  (51, 52) 
   microRNA-24  vascularization (51, 52) 
   microRNA-21  hypertrophy  (51, 52) 
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Figure legends 
Figure 1. 
Approaches of functional genomics. Panel A shows a conventional hypothesis-driven 
approach to investigate differentially expressed transcripts induced by a single 
experimental intervention. A more comprehensive way is to compare multiple 
expression patterns on different levels of functional genomics (mRNA, microRNA, 
long non-coding RNA) and proteomics and to integrate these “omics” data by 
network analysis to identify novel signaling hubs and networks. The array images 
were created by matrix2png algorithm (64). 
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